Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03201913
Recruitment Status : Recruiting
First Posted : June 28, 2017
Last Update Posted : August 15, 2018
Sponsor:
Information provided by (Responsible Party):
TTC Oncology, LLC

Brief Summary:
Phase1 study of TTC 352 for treatment of metastatic ER+ breast cancer.

Condition or disease Intervention/treatment Phase
Metastatic ER+ Breast Cancer Drug: TTC-352 Phase 1

Detailed Description:

This is open-label, accelerated dose escalation study of TTC 352, a selective human ER partial agonist for treatment of metastatic ER+ breast cancer in patients who received and progressed on at least two lines of endocrine therapy with one that included a CDK4/CDK6 inhibitor.

The primary objective of this study is to determine the maximum tolerated dose (MTD) of TTC-352 for the treatment of metastatic ER+ breast cancer progressing after endocrine therapy.

The maximum tolerated dose (MTD) of TTC-352 will be determined using initial single-patient cohort escalations until grade 2 toxicity, then expansion to a modified-Fibonacci dose-escalation 3+3 design. Patients enrolled at each dose escalation step must complete the first 28-day cycle of treatment without a dose-limiting toxicity (DLT), or be withdrawn because of a DLT, before additional patients may be enrolled for the next dose escalation step. The MTD dose level cohort will be expanded to a total of 9 patients, to further evaluate safety. In each cohort pharmacokinetics of TTC-352 will be evaluated.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label, accelerated dose escalation study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
Actual Study Start Date : December 11, 2017
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Accelerated dose escalation study

Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).

Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination.

Drug: TTC-352
Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.




Primary Outcome Measures :
  1. MTD [ Time Frame: 24 months ]
    The primary objective of this study is to determine the maximum tolerated dose (MTD) of TTC-352 for the treatment of metastatic ER+ breast cancer progressing after endocrine therapy


Secondary Outcome Measures :
  1. Best response to treatment [ Time Frame: 24 months ]
    Determine patient best response to treatment (complete response, partial response, stable disease or disease progression) after at least two 28-day cycles of treatment with TTC 352.

  2. PFS [ Time Frame: 24 months ]
    Determine durations of progression-free survival after at least two 28-day cycles of treatment with TTC 352

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 24 months ]
    Treatment-related adverse events as assessed by CTCAE v4.0 will be collected in presented in tabular form at the end of study.

  4. Maximum Plasma Concentration (Cmax) [ Time Frame: 24 months ]

    Blood samples will be collected at the following Cycle 1 time points:

    Day 1: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 after dosing (just before dosing on Day 2).

    Day 28: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 28 after dosing.

    TTC-352 blood levels will be measured at above time points and Cmax will be calculated.


  5. Half life [ Time Frame: 24 months ]

    Blood samples will be collected at the following Cycle 1 time points:

    Day 1: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 after dosing (just before dosing on Day 2).

    Day 28: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 28 after dosing.

    TTC-352 blood levels will be measured at above time points and half life of TTC-352 will be calculated.


  6. Area Under the Curve (AUC) [ Time Frame: 24 months ]

    Blood samples will be collected at the following Cycle 1 time points:

    Day 1: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12 and 24 after dosing (just before dosing on Day 2).

    Day 28: prior to dosing and at Hours 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24 and 28 after dosing.

    TTC-352 blood levels will be measured at above time points and AUC will be calculated.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. be ≥18 years of age;
  2. have a diagnosis of metastatic ER+ breast cancer in patients who received and progressed on at least two lines of endocrine therapy, with one that included a CDK4/CDK6 inhibitor (e.g., palbociclib or ribociclib);
  3. have metastatic disease evaluable on imaging studies;
  4. have a histologically confirmed diagnosis of ER+ breast cancer;
  5. have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 (Appendix II);
  6. have adequate hepatic function, defined as having a serum total bilirubin concentration ≤1.5mg/d, or ≤2 x the upper limit of normal (ULN) if associated with hepatobiliary metastases or Gilbert syndrome, and having serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations ≤2.5 × ULN, or ≤5 x ULN for patients with known hepatic metastases;
  7. have adequate renal function, defined as having a serum creatinine ≤1.5 × ULN and a creatinine clearance ≥40mL/min (estimated using the Cockcroft-Gault formula);
  8. have adequate hematologic function, defined as having a hemoglobin ≥8g/dL, an absolute neutrophil count (ANC) ≥1.0 × 109/L, and platelet count ≥75.0 x 109/L;
  9. be willing and able to comply with study visits and procedures;
  10. have read, understood and signed the informed consent form (ICF) approved by the Institutional Review Board (IRB);
  11. if a woman of childbearing potential (WOCP), not be pregnant (confirmed by a negative serum pregnancy test within 14 days of study entry and re-confirmed by a urine pregnancy test on the morning of Study Day 1, prior to the start of study treatment) and/or not be breast-feeding; [Note: Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are not considered to be a WOCP.]
  12. If a WOCP, agree to use during the study and for at least one month after the last dose of study drug a medically acceptable method of birth control [such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence.];
  13. if male (and whether or not surgically or medically sterile), agree to use during the study and for at least one month after the last dose of study drug a double barrier method of birth control (in addition to any other birth control method practiced by his partner) while engaging in sexual intercourse with a partner who is pregnant, possibly pregnant or able to become pregnant.

Exclusion Criteria:

  1. have received chemotherapy, hormonal therapy, biologic therapy, immunotherapy or radiation therapy within 14 days prior to the planned start of study treatment.
  2. have inadequate recovery* from adverse events resulting from previously-administered anti-cancer therapies; [*Note: Unless more specifically defined in Inclusion Criteria 6, 7 and 8 above, adequate recovery is defined as improvement to ≤ Grade 2 for any other hematologic toxicity and for peripheral neuropathy, and improvement to ≤ Grade 1 for any other non-hematologic toxicity.]
  3. have a history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism or retinal vein thrombosis, unless currently on anticoagulant therapy;
  4. have impending visceral crisis that requires chemotherapy;
  5. have known uncontrolled or symptomatic CNS metastases;
  6. have any clinically significant infection, defined as any acute viral, bacterial, or fungal infection that requires systemic treatment or have received any anti-infective treatment within 7 days prior to the screening visit;
  7. have any other severe, uncontrolled medical condition, including unstable congestive heart failure (Stage III-IV of the New York Heart Association Functional Classification (Appendix III))
  8. have a known or suspected allergy to the study drug or any study drug component;
  9. have any other medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, that may interfere with the interpretation of study results or that otherwise would, in the opinion of the Investigator, make study participation inappropriate;
  10. have any non-healing wound, fracture, or ulcer within 28 days prior to the planned start of study treatment;
  11. have received any other investigational drug within 28 days (or 5 half-lives, if longer) prior to the start of study screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03201913


Contacts
Layout table for location contacts
Contact: Arkadiusz Z Dudek, MD (612) 718-1960 aDudek@ttconcology.com
Contact: Robert P Venuti 919-619-7193 rVenuti@ttconcology.com

Locations
Layout table for location information
United States, Arizona
HonorHealth Research Institute Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Jose Ramirez, BS, CCRC    480-323-1229    Jose.ramirez@honorhealth.com   
Principal Investigator: Jasgit Sachdev, MD         
United States, Minnesota
HealthPartners Institute, Regions Cancer Care Center Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Hurley Randy, MD    651-254-3572    Randy.Hurley@HealthPartners.com   
Contact: Joanna Hill    (651) 254-2845    joanna.hill@parknicollet.com   
Principal Investigator: Randy Hurley, MD         
United States, South Dakota
Sanford Health Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Ashley Johnson, RN    605-312-3343    ashley.johnson9@sanfordhealth.org   
Contact: Staci Vogel    605-312-3336    staci.vogel@sanfordhealth.org   
Principal Investigator: Jonathan Bleeker, MD         
United States, Wisconsin
University of Wisconsin, Carbone Cancer Center Recruiting
Madison, Wisconsin, United States, 53792
Contact: Jeffrey Ockuly    608-262-3401    jcockuly@wisc.edu   
Principal Investigator: Ruth O'Regan, MD         
Sponsors and Collaborators
TTC Oncology, LLC
Investigators
Layout table for investigator information
Study Chair: Arkadiusz Z Dudek, MD TTC Oncology, LLC

Layout table for additonal information
Responsible Party: TTC Oncology, LLC
ClinicalTrials.gov Identifier: NCT03201913     History of Changes
Other Study ID Numbers: TTC-352-101
First Posted: June 28, 2017    Key Record Dates
Last Update Posted: August 15, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: At present TTC Oncology does not plan to share IPD with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases